Literature DB >> 7961992

Tyrosine 1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for the transduction of signals for cell motility and morphogenesis.

H Zhu1, M A Naujokas, E D Fixman, K Torossian, M Park.   

Abstract

The met proto-oncogene is a receptor tyrosine kinase for hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF is a multifunctional cytokine that stimulates mitogenesis, motility, invasion, and tubulogenesis of a spectrum of epithelial and endothelial cells in culture. Using a chimeric receptor (CSF-MET), containing the extracellular domain of the colony stimulating factor-1 (CSF-1) receptor fused to the transmembrane and intracellular domain of the Met receptor, we have previously demonstrated that activation of the Met kinase domain is sufficient to mediate the motility, invasion and morphogenic signals of HGF/SF in Madin-Darby canine kidney epithelial cells (MDCK). In this study we have analyzed the role of tyrosine phosphorylation of the Met receptor in the transmission of these signals by site-directed mutagenesis of specific tyrosine residues. Mutation of two tyrosine residues (tyrosine 1234 and tyrosine 1235), involved in activation of the catalytic activity of the kinase, abrogates the biological activity of the chimera. In addition, we have identified a single noncatalytic tyrosine residue (tyrosine 1356) in the carboxyl terminus of the Met receptor, that is essential for the biological activity of the chimeric receptor. Mutation of tyrosine 1356 to a nonphosphorylatable phenylalanine residue does not affect the exogenous kinase activity of the receptor toward enolase, but it impairs the ability of the mutant protein to associate with the adaptor protein Grb2, and MDCK cells expressing this mutant fail to scatter, invade, and form branching tubules in response to CSF-1. These results support a crucial role for tyrosine 1356 in activation of signaling pathways involved in the biological activity of the Met receptor in response to HGF/SF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961992

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

Review 1.  Roles of hepatocyte growth factor/scatter factor and transforming growth factor-beta1 in mammary gland ductal morphogenesis.

Authors:  J V Soriano; M S Pepper; L Orci; R Montesano
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

2.  The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase.

Authors:  C R Maroun; M Holgado-Madruga; I Royal; M A Naujokas; T M Fournier; A J Wong; M Park
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

3.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

4.  Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion.

Authors:  T M Fournier; L Lamorte; C R Maroun; M Lupher; H Band; W Langdon; M Park
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

5.  The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase.

Authors:  C R Maroun; M A Naujokas; M Holgado-Madruga; A J Wong; M Park
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

6.  Involvement of an SHP-2-Rho small G protein pathway in hepatocyte growth factor/scatter factor-induced cell scattering.

Authors:  A Kodama; T Matozaki; A Fukuhara; M Kikyo; M Ichihashi; Y Takai
Journal:  Mol Biol Cell       Date:  2000-08       Impact factor: 4.138

7.  Distinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis.

Authors:  Lisa S Lock; Christiane R Maroun; Monica A Naujokas; Morag Park
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

8.  Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.

Authors:  Yao Dai; Kyungmi Bae; Christine Pampo; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2012-03       Impact factor: 5.150

Review 9.  Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Authors:  Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-07-26       Impact factor: 4.929

10.  Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma.

Authors:  Yiru Xu; Jin Zhou; Thomas E Carey; Jonathan B McHugh; John J Voorhees; Gary J Fisher
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.